Sign In
Buy TNXP
$12.20
+0.190 (+1.58%)
At Close: Jun 22, 2026
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
04:05pm, Sunday, 24'th Mar 2024
Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
08:00am, Tuesday, 19'th Mar 2024
Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix's wholly-owned commercial subsidiary
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
08:00am, Tuesday, 12'th Mar 2024
Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second
Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and PTSD after civilian motor vehicle
TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation mAbs while addressing their thrombosis risk
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
02:12pm, Sunday, 25'th Feb 2024
In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
08:00am, Tuesday, 20'th Feb 2024
CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of develop
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
08:00am, Thursday, 15'th Feb 2024
Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigue Latest Phase 3 trial achieved primary endpoint (p=0.00005) Potential for FDA Approval in 2025 CHATHAM, NJ / ACCESS
Clinical results show that Tonyma™ has broad-spectrum activity, addressing the three core fibromyalgia symptoms: pain, fatigue, and sleep disturbance
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which NDA preparation is ongoing
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
08:00am, Thursday, 01'st Feb 2024
Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005) Combination of broad-spectrum relief and favorable tolerability seen as distinguishing, competitive features
Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID
07:00am, Wednesday, 31'st Jan 2024
Retrospective observational study of electronic medical records of more than 90 million people living in the U.S. Long COVID shares symptoms with chronic overlapping pain disorders like fibromyalgia a
Results from two positive Phase 3 studies point to Tonmya's (TNX-102 SL) potential as a new first-line medicine for chronic use in managing fibromyalgia, a debilitating condition suffered by 6-12 mill
TNX-102 SL is a Non-Opioid Analgesic that Demonstrated Daily Pain Reduction Over Placebo (Primary Endpoint, p = 0.00005) and Showed Positive Effects Across All Six Key Secondary Endpoints in Recently
CHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announ
